Ticker

Multi-site clinical study delivers strong performance data for Intelligent Fingerprinting Drug Screening System Multi-site clinical study delivers strong performance data for Intelligent Fingerprinting Drug Screening System

$5 Million Upfront at Closing and $5 Million Tranche Warrant Callable by the Company Following FDA 510(k) Clearance of Intelligent Fingerprinting Drug Screening System $5 Million Upfront at Closing and $5 Million Tranche Warrant Callable by the Company Following FDA 510(k) Clearance of Intelligent Fingerprinting Drug Screening System

BlackRock Inc. purchased a new stake in shares of Intelligent Bio Solutions Inc. (NASDAQ: INBS) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 29,061,242 shares of the company's stock, valued at approximately $149,956,000. BlackRock Inc. owned approximately 1,214.93% of Intelligent Bio

Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over 100,000 units

Shares of Intelligent Bio Solutions Inc. (NASDAQ:INBS) are surging Monday afternoon after the medical technology company announced a significant regulatory milestone for its rapid testing unit.